361 related articles for article (PubMed ID: 28899973)
1. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
2. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
3. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
4. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
5. Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy.
Hansen AF; Høiem TS; Selnaes KM; Bofin AM; Størkersen Ø; Bertilsson H; Wright AJ; Giskeødegård GF; Bathen TF; Rye MB; Tessem MB
NMR Biomed; 2023 May; 36(5):e4694. PubMed ID: 35032074
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
[TBL] [Abstract][Full Text] [Related]
8. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
9. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
[TBL] [Abstract][Full Text] [Related]
10. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
11. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
12. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
13. Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
Guo W; Sun S; Guo L; Song P; Xue X; Zhang H; Zhang G; Wang Z; Qiu B; Tan F; Xue Q; Gao Y; Gao S; He J
J Cancer Res Clin Oncol; 2020 Apr; 146(4):821-841. PubMed ID: 32103339
[TBL] [Abstract][Full Text] [Related]
14. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A.
Zhang R; Xu J; Zhao J; Bai JH
J Cell Biochem; 2018 Sep; 119(9):7256-7263. PubMed ID: 29761838
[TBL] [Abstract][Full Text] [Related]
15. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer.
Li X; Liu Y; Chen W; Fang Y; Xu H; Zhu HH; Chu M; Li W; Zhuang G; Gao WQ
Oncotarget; 2014 Oct; 5(19):9498-513. PubMed ID: 25237769
[TBL] [Abstract][Full Text] [Related]
16. The Inhibition of miR-144-3p on Cell Proliferation and Metastasis by Targeting TOP2A in HCMV-Positive Glioblastoma Cells.
Song J; Ma Q; Hu M; Qian D; Wang B; He N
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544723
[TBL] [Abstract][Full Text] [Related]
17. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
18. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
[TBL] [Abstract][Full Text] [Related]
19. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]